Nasopharyngeal Cancer - Global Pipeline Review (H1 2019) by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 28, 2019--
The “Nasopharyngeal Cancer - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Nasopharyngeal Cancer - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 22, 10, 3, 10, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 3, 7 and 1 molecules, respectively.
Reasons to Buy
Key Topics Covered
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/liecpf
View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005337/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/28/2019 06:38 AM/DISC: 05/28/2019 06:38 AM